

SAMRC InfoSpace

Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors

Item Type	Article
Authors	Sahu, N.U;Singh, V;Ferraris, D.M;Rizzi, M;Kharkar, P.S
Citation	Sahu NU, Singh V, Ferraris DM, Rizzi M, Kharkar PS. Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1714-1718. doi: 10.1016/j.bmcl.2018.04.045.
Publisher	Elsevier
Download date	2026-06-06 02:34:41
Link to Item	https://pubmed.ncbi.nlm.nih.gov/29699922/



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmclHit discovery of *Mycobacterium tuberculosis* inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitorsNiteshkumar U. Sahu^a, Vinayak Singh^{b,c}, Davide M. Ferraris^d, Menico Rizzi^d, Prashant S. Kharkar^{a,*}^a Department of Pharmaceutical Chemistry, SPP School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (West), Mumbai 400 056, India^b Drug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, Cape Town, South Africa^c South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa^d Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Via Bovio 6, 28100 Novara, Italy

ARTICLE INFO

Article history:

Received 20 February 2018

Revised 13 April 2018

Accepted 17 April 2018

Available online 18 April 2018

Keywords:

Tuberculosis

Anti-tubercular

IMPDH

1,2,3-Triazole

Mycobacterium tuberculosis

GuaB2

ABSTRACT

Tuberculosis remains a global concern. There is an urgent need of newer antitubercular drugs due to the development of resistant forms of *Mycobacterium tuberculosis* (*Mtb*). Inosine 5'-monophosphate dehydrogenase (IMPDH), *guaB2*, of *Mtb*, required for guanine nucleotide biosynthesis, is an attractive target for drug development. In this study, we screened a focused library of 73 drug-like molecules with desirable calculated/predicted physicochemical properties, for growth inhibitory activity against drug-sensitive *Mtb*H37Rv. The eight hits and mycophenolic acid, a prototype IMPDH inhibitor, were further evaluated for activity on purified *Mtb*-GuaB2 enzyme, target selectivity using a conditional knockdown mutant of *guaB2* in *Mtb*, followed by cross-resistance to IMPDH inhibitor-resistant SRMV2.6 strain of *Mtb*, and activity on human IMPDH2 isoform. One of the hits, **13**, a 5-amidophthalide derivative, has shown growth inhibitory potential and target specificity against the *Mtb*-GuaB2 enzyme. The hit, **13**, is a promising molecule with potential for further development as an antitubercular agent.

© 2018 Elsevier Ltd. All rights reserved.

Introduction

Tuberculosis (TB), an infectious disease caused by the bacillus *Mycobacterium tuberculosis* (*Mtb*), is the ninth leading cause of death worldwide and number one from a single infectious agent, ranking above HIV/AIDS.¹ The increased prevalence of infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of *Mtb*, with limited treatment choices, is a wake-up call urging the development of more effective antitubercular agents, ideally with novel mechanism(s) of action. This is not the end of the story! Emergence of totally drug-resistant (TDR)-TB in which *Mtb* is resistant to all first- and second-line antitubercular drugs has terrified the healthcare professionals.²

Tuberculosis, mainly being the disease of the developing or underdeveloped nations, was a neglected disease in terms of drug discovery. Bedaquiline,³ a recently approved antitubercular drug, has shown promise in treating TB. Several drug repurposing campaigns of approved drugs^{4,5} are likely to offer potential alternatives for the treatment of TB. In light of the fact that the strategies involving development of potent and target-selective enzyme

inhibitors which arrested essential biochemical processes, failed miserably in whole-cell *Mtb* assays,⁶ newer molecules with novel mechanism(s) of action are essential to tackle TB menace. One such pathway is purine nucleotide biosynthesis. The enzyme inosine 5'-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) catalyzes a crucial step in the biosynthesis of guanine nucleotides leading to oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP) with concomitant reduction of nicotinamide adenine dinucleotide (NAD⁺) to reduced nicotinamide adenine dinucleotide (NADH).⁸ The XMP is further converted into guanosine 5'-monophosphate (GMP) by GMP synthase. Inhibition of IMPDH leads to depletion of guanine nucleotide pool, affecting cell division, and ultimately inhibition of cell proliferation.

The enzyme IMPDH, thus, is an interesting target for anticancer, antiviral, immunosuppressive and antimicrobial therapies.⁹ Mycophenolic acid (MPA, **1**, Fig. 1) is an IMPDH inhibitor widely used as immunosuppressant and antiviral drug.¹⁰ Three genes encode IMPDH in *Mtb*, namely, *guaB1* (*Rv1843c*), *guaB2* (*Rv3411c*) and *guaB3* (*Rv3410c*). However, only *guaB2* has shown the IMPDH activity.^{11,12}

Chen et al. reported mycophenolic adenine dinucleotides (MAD1) as a *Mtb* IMPDH inhibitors, where the pyrophosphate linker in NAD⁺ was replaced with isosteric 1,2,3-triazole

* Corresponding author.

E-mail address: prashant.kharkar@nmims.edu (P.S. Kharkar).




Fig. 1. Mycophenolic acid (MPA) and earlier *Mtb*IMPDPH inhibitors.




Fig. 2. Chemotypes observed in Cp- and bacterial IMPDPH inhibitors.




Fig. 3. Few *Mtb*IMPDPH (GuaB2) inhibitors.

(2, $K_i^{app} = 1.5$ μ M).¹³ Recently, several *Mtb*-GuaB2 inhibitors have been identified in a target-based high-throughput resistance-based phenotypic screen.¹⁴ The identified hits are represented by compound 3. In similar studies, *Cryptosporidium parvum* IMPDPH (CpIMPDPH) selective inhibitors belonging to five chemical series (4–8, Fig. 2) were screened against *Mtb*IMPDPH.⁷ Few of these molecules were potent inhibitors (9, P series and 10, Q series, Fig. 3).¹⁰ Another series, 1*H*-benzo[d]imidazole, of *Mtb*IMPDPH was reported with submicromolar inhibition constants (11, Fig. 3).¹⁵

Careful examination of the common structural features of the lead molecules (3, 9, 10 and 11, Figs. 1 and 3), the authors adopted a pharmacophore-based design strategy for GuaB2 inhibitors – two aromatic moieties connected with a linker (Fig. 4). Indeed, many human IMPDPH2 (*h*IMPDPH2) inhibitors possessed similar features and the nature of the linker was shown to be crucial in modulating potency and selectivity, if any.^{16,17} Learning from previous experience with IMPDPH inhibitors, a subset of our in-house library (#60) matching the pharmacophore criteria along with few compounds





Fig. 4. Pharmacophoric features for *Mtb*IMPDPH (GuaB2) inhibitors.


similar to MPA (#12) were initially screened for *anti-Mtb* activity in drug-sensitive *Mtb* H37Rv strain, followed by evaluation of the hits (#8) on two derivatives of *Mtb* H37Rv: (i) for target selectivity – *guaB2-B3* Tet-OFF *attB::guaB3*, a conditional knockdown mutant (cKD, *guaB2* Tet-OFF) in which *Mtb*IMPDPH levels are depleted by transcriptional silencing of the IMPDPH-encoding gene, *guaB2* and (ii) for cross-resistance – SRMV2.6 this strain expresses the mutant *Mtb*IMPDPH Y487C, which is resistant to an isoquinoline sulfonamide *Mtb*IMPDPH2 inhibitor.⁶ Here, we report the synthesis and biological testing of the hits discovered in whole cell-based and target (*Mtb*IMPDPH, GuaB2)-specific assays.

Methods


Compounds 12 and 13 were synthesized by reacting 5-aminophthalide (11a) and substituted acid chlorides, in presence of pyridine (Scheme 1). The synthesis of 1,2,3-triazole derivatives proceeded in two steps as described in Schemes 2–4. First, intermediate 15 was synthesized using 14, hydrazine hydrate and triethyl orthoacetate. Further 15, α - and β -naphthols (17a and 17b, respectively) were alkylated with propargyl chloride in presence of anhydrous K_2CO_3 and DMF to yield 16 and 18a–b (Schemes 2 and 3). Substituted benzyl azides (20a–e, Scheme 3) prepared from corresponding benzyl bromides (19a–e), were further reacted with




Scheme 1. ^aSynthesis of arylalkyl amides 12–13 ^aReagents and conditions. a. substituted acid chloride, pyridine, THF, 0 °C to RT, overnight.



Scheme 2. ^aSynthesis of 1,2,3-triazole analogs ^aReagents and conditions. a. $NH_2-NH_2 \cdot H_2O$, EtOH, Reflux; b. triethyl orthoacetate; c. propargyl chloride, K_2CO_3 , DMF, 12 h.



Scheme 3. ^aSynthesis of 1- and 2-(prop-2-ynoxy)naphthalene. ^aReagents and conditions. a. Propargyl chloride, K_2CO_3 , DMF, 12 h.



Scheme 4. ^aSynthesis of title compounds. ^aReagents and conditions a. NaN_3 , *i*-PrOH:H₂O (4:1); b. **16/18a/18b**, $\text{Cu}(\text{OAc})_2$, *t*-BuOH:H₂O (3:1), RT, 8 h.

16 and **18a–b** in *tert*-butanol and water (3:1 mixture) along with $\text{Cu}(\text{OAc})_2$ to yield title compounds **21a–d** and **22a–b** (Scheme 4) in 55–88% yield (Table 1). The synthetic procedures can be found in the Supporting Data section.

Drug susceptibility testing

Unless indicated otherwise, minimum inhibitory concentration (MIC) testing was carried out by broth microdilution using the Ala-

marBlue (AB, Invitrogen) assay.⁶ For pairwise combination (checkerboard) assays, a two-dimensional array of serial dilutions of test compound and anhydrotetracycline (ATc) was prepared in 96-well plates, as previously described.^{6,18} The results are shown in Table 1 and Fig. 5.

The hits were evaluated for antibacterial activity against five bacterial strains at 60–146 μM (32 $\mu\text{g}/\text{mL}$) concentration. The bacterial strains included one Gram-positive (*Staphylococcus aureus*, MRSA) and four Gram-negative (*Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa*).¹⁹ The results are summarized in Table 3S (Supplementary Data).

Biochemical assay

All the hits were further tested in our laboratory for human IMPDH2 inhibition according to protocols reported previously.^{16,17} The results are shown in Fig. 6 and Table 3S (Supplementary Data).

Table 1
Anti-*Mtb* activity of the hits.

Compound No.	Structure	MIC ₉₀ (μM)		GuaB2	
		H37Rv	SRMV2.6	% Inhibition (50 μM)	IC ₅₀ (μM)
1		50	50	83.0 ± 5.7	27.2 ± 0.1
12		100	100	95.2 ± 0.4	6.2 ± 0.1
13		100	100	99.9 ± 0.6	3.04 ± 0.03
21a		50	>100	ni	nd
21b		100	100	72.6 ± 8.4	nd
21c		50	100	35.0 ± 6.4	nd
21d		100	>100	71.0 ± 0.6	nd
22a		100	>100	43.5 ± 3.1	174.7 ± 0.1
22b		50	>100	52.4 ± 8.0	nd

^a ni – no inhibition, nd – not determined.




Fig. 5. Effects of *guaB2* silencing on susceptibility of *Mtb* to a. **1**; b. **12**; c. **13** and d. **21a**. Values in the parentheses represent ATc concentration (ng/mL). The red-dashed lines represent MIC₉₀ values.

Inhibition of tested compounds on recombinant *Mtb*-GuaB2 enzymatic activity was assayed as previously reported protocol.⁶

Results and discussion

From our in-house library generated for the human and *Staphylococcus aureus* IMPDH (*Sal*IMPDH) inhibitor programs, we selected 60 molecules based on their pharmacophoric features for further screening against *Mtb*. Mycophenolic acid (**1**), a prototypical IMPDH inhibitor, was included in this set since *Mtb*IMPDH inhibitors based on MPA structure (**2**, Fig. 1) are




Fig. 6. % hIMPDPH2 inhibition by the hits at 10 μM concentration.

known.¹³ We also included 12 molecules (alkanoic acids) structurally similar to MPA in the screening set. The molecular property ranges for these molecules are shown in Table 2S (Supplementary Data). The average logP for the screening set was 2.899 (Min. 0.2022, Max. 5.325). The MPA analogs exhibited lower logP values due to alkanolic acid functionality. None of these molecules exhibited appreciable anti-*Mtb* activity against *Mtb* H37Rv strain (MIC₉₀ > 100 μM) (Table 1S). This was not surprising owing to the higher lipophilicity required for crossing *Mtb* cell wall. The screening results for the hits (MIC₉₀ ≤ 100 μM) are summarized in Table 1.

Of the nine hits, out of 73 molecules screened (Table 1), **21a**, **21c** and **22b** (logP between 3.5 and 4.5) were twofold more potent than others (**13**, **21d**: logP between 2.5 and 3.5; and **21b**: logP > 4.5) except **1** (logP 2.679). Compound **12** (logP 3.669) exhibited MIC₉₀ of 100 μM . This could be due to its lower predicted logS (−0.228). Presence of a polar substituent (−OMe, −Cl) at 3rd position on the arylalkyl moiety attached to triazole N (**21a**, **21c** and **22b**) could contribute to higher potency in the 1,2,3-triazole series. Moving this substituent to the 4th position led to complete loss of activity (MIC₉₀ > 100 μM) (Table 1S). A planar [mono- or bicyclic (hetero)aromatic] substituent on the left side of the linker was tolerated for anti-*Mtb* activity in the hits (**12**, **21c** and **22b**, Table 1). Replacing this aromatic ring with alicyclic/spirocyclic ring(s) abolished the anti-*Mtb* activity (Table 1S).

The hits were further taken up to test the activity against GuaB2 in target-specific whole-cell *Mtb* assays. The data of the checkerboard assay (Anhydrotetracycline, ATc, vs compounds) against *guaB2* Tet-OFF are presented in Fig. 5 (**1**, **12**, **13** and **21a**) and Figs. 1S (**21b**, **21c** and **21d**) and 2S (**22a** and **22b**) (Supplementary Data). The *guaB2* Tet-OFF strain was a *guaB2* cKD mutant in which *guaB3* expression was unaffected by ATc (i.e., upon ATc treatment only *guaB2* expression was down regulated).⁶ The data clearly demonstrated that the transcriptional silencing of *guaB2* (upon ATc addition) in *Mtb* confers hypersensitivity (shift of MICs from left to right) to the compounds (more profound with **13**, MIC₉₀ reduced from 100 μM in WT strain to 12.5 μM upon depletion of *guaB2* – both at 0.15 and 0.31 ng/mL ATc). Compounds **1**, **12** and **13** definitely were active against *guaB2*, whereas the activity of other compounds at *guaB2* could not be ascertained from the data obtained from checkerboard assays.

The hits (Table 1) were tested against SRMV2.6 strain (nsSNP in *guaB2*, Y487C)¹⁸ which showed resistance to earlier lead compound VCC234718, an isouquinoline sulfonamide. Here, no significant deviation in the MICs was observed (Table 1), suggesting the unique binding of the hits to the GuaB2 compared to VCC234718. Further these hits were screened for *Mtb*-GuaB2 inhibition assay, where eight molecules inhibited *Mtb*-GuaB2 at 50 μM . Molecules exhibit-

ing more than 50% inhibition were further subjected for IC₅₀ determination, out of which **1**, **12** and **13** showed promising activity 27.2, 6.2 and 3.2 μM, respectively.

The hits were further tested for *h*IMPDPH2 inhibition. As seen in Fig. 6, compound **1** exhibited the highest *h*IMPDPH2 inhibition at 10 μM. In addition, **12**, **22a** and **22b** showed appreciable inhibition (23, 14.75 and 24.93%, respectively, Table 3S, Supplementary Data), compared to other hits (*h*IMPDPH2 inhibition ≤ 0.1% at 10 μM). The authors did not pursue these 'nonselective' compounds (**12**, **22a** and **22b**) further and focused the attention on the remaining hits. Compound **13**, due to its potency at GuaB2 (IC₅₀ = 3.04 ± 0.03 μM) and selectivity (over *h*IMPDPH2) was studied further. The data (Tables 1 and 3S), thus, affirms the selectivity of **13** for GuaB2 over *h*IMPDPH2.

None of the hits showed any antibacterial and antifungal activity at 60–146 μM (32 μg/mL) concentration.¹⁹ No further studies were carried out for evaluating target activity against *Sal*IMPDPH since the hits were inactive.

Overall, our efforts directed towards discovering hit molecules targeting *Mtb*-GuaB2 led to fruition. We have successfully identified hits belonging to 5-amidophthalide (**13**, Table 1) series which were selective for GuaB2 over *h*IMPDPH2. Although compounds from 1,2,3-triazole series showed appreciable anti-*Mtb* activity (**21a**, **21c** and **22b**), their activity at GuaB2 remains to be proved. Earlier, Shaikh et al. reported antitubercular activity of 1,2,3-triazole derivatives against *Mtb H37Rv* strain (MIC 5.8–29.9 μg/mL).²⁰ Similarly, Stanley et al. identified novel *Mtb* growth inhibitors belonging to 1,2,3-triazole series.²¹ Interestingly, the nitrotriazole compound was shown to inhibit DprE1 (decaprenyl-phosphoryl-β-D-ribose-2'-epimerase) enzyme required for cell wall biosynthesis in *Mtb*. Future work in this direction is likely to yield desirable results.

Conclusion

The systematic selection and biological screening of in-house library of potential IMPDPH inhibitors led to the identification of novel and selective inhibitors of *Mtb*IMPDPH encoded by *guaB2* over *h*IMPDPH2. The hits belonged to 5-amidophthalide and 1,2,3-triazole series. Further screening of the hits in target-specific assays confirmed significant activity of **13** on *Mtb*-GuaB2. The triazole hits, despite more potency, failed to establish clear connection with GuaB2 inhibition and anti-*Mtb* activity. The hits did not exhibit significant inhibition against drug-resistant SRMV2.6 strain, pointing to unique mode of GuaB2 inhibition. The hits can be further exploited in a typical medicinal chemistry program to enhance potency and target selectivity.

Notes

NS received PhD fellowship from SVKM's NMIMS, Mumbai. MR is the recipient of the EU FP7MM4TB Grant No. 260872. The authors confirm that this article content has no conflict of interest.

Acknowledgements

NS and PK appreciate the help received from CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The University of Queensland (Australia), for antibacterial and antifungal screening. NS and PK deeply acknowledge the help received from Dr. Kapil Juvale, Assistant Professor with SVKM's NMIMS, SPP School of Pharmacy and Technology Management, Mumbai, India and Mr. Chetan Shah, PhD student in PK's group during *h*IMPDPH2 inhibition studies. The South African Medical Research Council (SAMRC) is acknowledged for funding. PK thanks Optibrium Ltd., USA, for providing one-month demo license of StarDrop™.

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.bmcl.2018.04.045>.

References

1. WHO. *Global Tuberculosis Report 2017*. 2017.
2. Parida SK, Axelsson-Robertson R, Rao MV, et al. *J Intern Med*. 2017;277:388.
3. Mdluli K, Kaneko T, Upton A. *Cold Spring Harb Perspect Med*. 2015;5:a021154.
4. Maitra A, Bates S, Kolvekar T, Devarajan PV, Guzman JD, Bhakta S. *Int J Infect Dis*. 2015;32:50.
5. Sahu NU, Kharkar PS. *Curr Top Med Chem*. 2016;16:2069.
6. Singh V, Donini S, Pacitto A, et al. *ACS Inf Dis*. 2017;3:5.
7. Shah CS, Kharkar P. *Future Med Chem*. 2015;7:2131.
8. Shu Q, Nair V. *Med Res Rev*. 2008;28:219.
9. Hedstrom L. *Chem Rev*. 2009;109:2903.
10. Makowska-Grzyska M, Kim Y, Gorla SK, et al. *PLoS One*. 2015;10:e0138976.
11. Usha V, Gurucha SS, Lovering AL, et al. *Microbiology*. 2011;157:290.
12. Usha V, Hobrath JV, Gurucha SS, Reynolds RC, Besra GS. *PLoS One*. 2012;7:e33886.
13. Chen L, Wilson DJ, Xu Y, et al. *J Med Chem*. 2010;53:4768.
14. Cox JA, Mugumbate G, DelPeral LV, et al. *Sci Rep*. 2016;6:38986.
15. Pissinate K, Rostirolla DC, Pinheiro LM, et al. *J Braz Chem Soc*. 2015;26:1357.
16. Dunkern T, Chavan S, Bankar D, et al. *J Enzyme Inhib Med Chem*. 2014;29:408.
17. Dunkern T, Prabhu A, Kharkar PS, et al. *J Comput Aided Mol Des*. 2012;26:1277.
18. Singh V, Breck M, Mukherjee R, et al. *Chem Biol*. 2015;22:63.
19. Antimicrobial screening was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The University of Queensland (Australia).
20. Shaikh MH, Subhedar DD, Nawale L, et al. *Med Chem Commun*. 2015;6:1104.
21. Stanley SA, Grant SS, Kawate T, et al. *ACS Chem Biol*. 2012;7:1377.